Correction to: Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy (Nature Communications, (2022), 13, 1, (6357), 10.1038/s41467-022-33891-9)

  • Yuanhuan Yu
  • , Xin Wu
  • , Meiyan Wang
  • , Wenjing Liu
  • , Li Zhang
  • , Ying Zhang
  • , Zhilin Hu
  • , Xuantong Zhou
  • , Wenzheng Jiang
  • , Qiang Zou
  • , Fengfeng Cai*
  • , Haifeng Ye*
  • *Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-022-33891-9, published online 26 October 2022 The original version of the manuscript contained errors in Fig. 3, in Supplementary Fig. 14, and in Source Data for Fig. 3c. Original Fig. 3 has now been replaced with the corrected version in the Article file (PDF and HTML versions) and an updated Supplementary Information file and Source Data file have been made available. In detail: In Fig. 3b, the image of one mouse (third from left) in the group “G5 FLICs-loaded hydrogel (FRL)” for Day 10 was incorrect and has been replaced with the correct image. The above applies also for Supplementary Fig. 14 that contains magnified images of the mice displayed in Fig. 3b. The correct bioluminescence value for the mouse above has been taken into account (information updated in the Source Data file for Fig. 3c) and Fig. 3c revised accordingly. In Fig. 3b, the image of one mouse (third from left) in the group “G5 FLICs-loaded hydrogel (FRL)” for Day 10 was incorrect and has been replaced with the correct image. The above applies also for Supplementary Fig. 14 that contains magnified images of the mice displayed in Fig. 3b. The correct bioluminescence value for the mouse above has been taken into account (information updated in the Source Data file for Fig. 3c) and Fig. 3c revised accordingly.

Original languageEnglish
Article number3686
JournalNature Communications
Volume15
Issue number1
DOIs
StatePublished - Dec 2024

Fingerprint

Dive into the research topics of 'Correction to: Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy (Nature Communications, (2022), 13, 1, (6357), 10.1038/s41467-022-33891-9)'. Together they form a unique fingerprint.

Cite this